|1.||Uckun, Fatih M: 8 articles (11/2010 - 06/2003)|
|2.||Narula, Satwant: 4 articles (08/2015 - 04/2012)|
|3.||Lou, Yan: 4 articles (01/2015 - 02/2011)|
|4.||Byrd, John C: 4 articles (01/2015 - 02/2014)|
|5.||Chang, Betty Y: 4 articles (08/2014 - 08/2013)|
|6.||Blum, Kristie A: 3 articles (12/2015 - 08/2013)|
|7.||DeMartino, Julie: 3 articles (08/2015 - 04/2012)|
|8.||Woods, John: 3 articles (08/2015 - 04/2012)|
|9.||Liu, Lichuan: 3 articles (06/2015 - 07/2011)|
|10.||Clow, Fong: 3 articles (04/2015 - 08/2013)|
05/01/2015 - "Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas."
08/01/2014 - "We also discuss recent findings that reveal a major role for Btk (Bruton's tyrosine kinase) in both lymphocytic and myeloid forms of human leukaemias and lymphomas."
02/01/2011 - "Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases. "
01/01/2015 - "Here, we review novel therapeutic agents in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma, which have emerged in the past decade and discuss their comparative efficacy and safety, with emphasis on a Bruton's tyrosine kinase (BTK) inhibitor, which has been recently approved by the US FDA, specifically for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. "
11/01/2010 - "Bruton's tyrosine kinase (BTK) has emerged as a new anti-apoptotic molecular target for the treatment of B-lineage leukemias and lymphomas. "
08/19/2015 - "Bruton's tyrosine kinase (Btk) is intricately involved in anti-apoptotic signaling pathways in cancer and in regulating innate immune response. "
06/01/2015 - "Hematologic cancers can occur from the overactivity of Bruton's tyrosine kinase, a proto-oncogene in blood cell maturation. "
04/15/2015 - "Ibrutinib is a clinically approved Bruton's tyrosine kinase inhibitor that inhibits mast cells and tumor progression in a mouse model of β-cell tumorigenesis. "
04/09/2015 - "MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. "
01/01/2015 - "As a critical regulator of the B-cell receptor signaling pathway, Bruton's tyrosine kinase (Btk) has attracted intensive drug discovery efforts for treating B-cell lineage cancers and autoimmune disorders. "
|3.||B-Cell Lymphoma (Lymphoma, B Cell)
03/26/2015 - "Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase, a key enzyme in the signaling pathway downstream of B-cell receptor, is an effective treatment against many types of B-cell lymphomas. "
01/01/2013 - "ABSTRACT Bruton's tyrosine kinase (Btk) is a signaling molecule that plays important roles in B-1 B cell development and innate myeloid cell functions and has recently been identified as a target for therapy of B cell lymphomas. "
08/01/2014 - "Ibrutinib, a novel first-in-human Bruton's tyrosine kinase (BTK) inhibitor, has progressed into phase III trials after early-phase clinical studies demonstrated effective target inhibition, increased tumor response rates, and significant improvement in survival, particularly in patients with indolent B-cell lymphomas. "
08/01/2013 - "Such new targeted agents, including those that inhibit the function of Spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinases (PI3K), and B-cell lymphoma 2 (BCL-2), along with the current standard therapy comprising chemo-immunotherapies with or without B-cell depleting biologic agent rituximab (anti-CD20 monoclonal antibody), should expand the armamentarium for CLL therapy. "
|4.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
06/12/2014 - "Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). "
12/01/2015 - "Ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, and idelalisib, a selective inhibitor of PI3Kδ, have obtained regulatory approval in chronic lymphocytic leukemia. "
03/01/2015 - "Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia."
03/20/2014 - "The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with chronic lymphocytic leukemia. "
02/20/2014 - "Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)."
07/01/2011 - "Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy."
04/01/2012 - "Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA). "
04/01/2012 - "Bruton's tyrosine kinase (Btk) has been the most widely studied due to the critical role of this kinase in B-cell development and recent evidence showing that blocking Btk signaling is effective in ameliorating lymphoma progression and experimental arthritis. "
|1.||Proteasome Endopeptidase Complex (Proteasome)
|2.||Immunologic Factors (Immunomodulators)
|5.||Bruton type agammaglobulinemia
|7.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|9.||Janus Kinase 3
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|2.||Heterologous Transplantation (Xenotransplantation)